Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma

By on    Pharma & Biotech  

Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma

Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or […]

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

By on    Features & Analysis  

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a […]